Novartis boosts involvement in anti-Covid treatment
Swiss pharmaceutical company Novartis says it has signed a deal with biotech firm Molecular Partners to develop, manufacture and commercialise an anti-Covid-19 treatment drug.
The Basel-based company said the option and licence agreement was aimed at boosting a programme consisting of two antiviral therapeutic candidates, MP0420 and MP0423.
“It is clear that this pandemic calls for not just scientific solutions, but also for collaboration between companies to provide treatments in an area of high unmet need,” Novartis said in a statement publishedExternal link on Wednesday.
Molecular Partners will be responsible for the conduct of phase 1 and 2 trials.
Under the terms of the agreement, Molecular Partners will receive an initial payment of CHF60 million ($66.1 million). If Novartis takes up the option to both drugs, it will pay another CHF150 million to the biotech company.
In August, the Swiss government signed an agreement with Molecular Partners for priority access to a drug being developed to treat those severely ill with Covid-19.
It gives Switzerland access to the first 200,000 doses of the medicine, as well as up to three million further doses when requested.
SWISS is airline ‘group flagship’ says Lufthansa boss
This content was published on
Despite challenges, Lufthansa and its most important subsidiary, Swiss International Airlines, promise increased satisfaction and continued growth.
Swiss rediscover communist zeal after 84-year hiatus
This content was published on
Over 300 participants founded the Revolutionary Communist Party (RKP) at its congress in Burgdorf in canton Bern at the weekend.
This content was published on
Nemo brought the Eurovision Song Contest to Switzerland with a victory on Saturday evening in Malmö, Sweden. It is Switzerland's third victory in the history of the music contest.
Switzerland abstains from vote on Palestinian bid for full UN membership
This content was published on
On Friday, Switzerland abstained from the vote at the General Assembly on granting the Palestinians new rights at the United Nations (UN).
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Roche bids to co-develop potential oral Covid-19 treatment
This content was published on
The Basel-based company has partnered with Atea Pharmaceuticals to develop, manufacture and distribute the latter’s oral anti-Covid-19 treatment.
Switzerland fast-tracks antiviral medication against Covid-19
This content was published on
Swissmedic, the agency that oversees the use of medicaments in Switzerland, took days to fast-track approval of the drug, which is produced under the brand name Veklury by US biopharmaceutical company Gilead Sciences. The application for its extended use was only received on Monday. It can now be used for a limited period of time to…
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.